Dermira Prices $126 Million Public Offering of Common Stock

MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Dermira from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $126 million. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock, on the same terms and conditions. All of the shares will be offered and sold by Dermira.

Leerink Partners LLC, Cowen and Company, LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.

The public offering is being made pursuant to a shelf registration statement on Form S-3 that was filed by Dermira with the Securities and Exchange Commission (“SEC”) on November 2, 2015, as amended by Amendment No. 1 filed with the SEC on November 13, 2015, and declared effective by the SEC on November 24, 2015. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at [email protected], or by telephone at 800-808-7525, ext. 6142; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 631-274-2806; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 212-518-9658, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy Dermira’s common stock, nor shall there be any sale of Dermira’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Dermira Contact
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer
650.421.7200
[email protected]

Investor Contact
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]

You May Also Be Interested In

• Amylyx prices $500M stock offering at $35.50 per share
• Greenland Mines announces 1-for-50 reverse split, field updates
• RenovoRx receives USPTO notice of allowance for RenovoCath patent